InterPAD - DETAILS

Alogliptin, 850649-61-5, alogliptina, (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile, Alogliptin [INN], UNII-JHC049LO86, alogliptine, alogliptinum, JHC049LO86, SYR322, CHEBI:72323, HSDB 8203, 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile, DTXSID90234130, 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile, 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile, vipidia, 1246610-75-2, alogliptin tartrate, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile, 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; (R)-2-[6-[3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]benzonitrile; 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; Alogliptin, ALOGLIPTIN [MI], ALOGLIPTIN [VANDF], ALOGLIPTIN [WHO-DD], SCHEMBL121028, CHEMBL376359, GTPL6319, BDBM16285, HY-A0023A, A10BH04, DTXCID90156621, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, 1347001-80-2, AMY22119, EX-A5446, Alogliptin pound SYR-322 pound(c), MFCD09833196, s2868, s5365, AKOS025149226, CCG-267914, CCG-267915, CS-1617, DB06203, NCGC00386215-04, NCGC00386215-05, AC-26300, AS-19582, NS00071194, SW219186-1, EN300-6482025, Q4734170, BRD-K83003151-057-02-4, 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile, Benzonitrile, 2-((6-((3R)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl)-

No.	Title	Href
1	DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50(D1):D1200-D1207. doi:10.1093/nar/gkab880	`Click`

No.

Title

Href

DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 2022;50(D1):D1200-D1207. doi:10.1093/nar/gkab880

Click

Name	Alogliptin
PubChem CID	11450633
Molecular Weight	339.4g/mol
Synonyms	Alogliptin, 850649-61-5, alogliptina, (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile, Alogliptin [INN], UNII-JHC049LO86, alogliptine, alogliptinum, JHC049LO86, SYR322, CHEBI:72323, HSDB 8203, 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile, DTXSID90234130, 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile, 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile, vipidia, 1246610-75-2, alogliptin tartrate, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile, 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; (R)-2-[6-[3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]benzonitrile; 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]benzonitrile; Alogliptin, ALOGLIPTIN [MI], ALOGLIPTIN [VANDF], ALOGLIPTIN [WHO-DD], SCHEMBL121028, CHEMBL376359, GTPL6319, BDBM16285, HY-A0023A, A10BH04, DTXCID90156621, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, 1347001-80-2, AMY22119, EX-A5446, Alogliptin pound SYR-322 pound(c), MFCD09833196, s2868, s5365, AKOS025149226, CCG-267914, CCG-267915, CS-1617, DB06203, NCGC00386215-04, NCGC00386215-05, AC-26300, AS-19582, NS00071194, SW219186-1, EN300-6482025, Q4734170, BRD-K83003151-057-02-4, 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile, Benzonitrile, 2-((6-((3R)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl)-
Drug Type	Small molecule
Formula	C₁₈H₂₁N₅O₂
SMILES	CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
InChI	1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
InChIKey	ZSBOMTDTBDDKMP-OAHLLOKOSA-N
CAS Number	850649-61-5
ChEMBL ID	CHEMBL376359
ChEBI ID	CHEBI:72323
TTD ID	D0NJ5H
Drug Bank ID	DB06203
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Alogliptin
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.